Business

Announcement on Voluntary Disclosure of the Notice of Acceptance for Registration and Marketing License of FB3002 Loxoprofen Sodium Patches Obtained for Drug Manufactured in China

Announcement on Voluntary Disclosure of the Notice of Acceptance for Registration and Marketing License of FB3002 Loxoprofen Sodium Patches Obtained for Drug Manufactured in China

articleFrontier Biotechnologies Inc. Class AJanuary 20, 20254/news/announcement-on-voluntary-disclosure-of-the-notice-of-acceptance-for-registration-and-marketing-license-of-fb3002-loxoprofen-sodium-patches-obtained-for-drug-manufactured-in-china
Announcement on Voluntary Disclosure of the Notice of Acceptance for Registration and Marketing License of FB3002 Loxoprofen Sodium Patches Obtained for Drug Manufactured in China

About this update from Frontier Biotechnologies Inc. Class A

Announcement on Voluntary Disclosure of the Notice of Acceptance for Registration and Marketing License of FB3002 Loxoprofen Sodium Patches Obtained for Drug Manufactured in ChinaThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Frontier Biotechnologies Inc. Class A